CRISPR-Cas9 Knockout of a Novel Cancer Checkpoint Unleashes T Cell Reactivity Against Solid Tumours Researchers have shown that CRISPR-Cas9 knockout of CISH, a negative regulator of T cell immunity, increases the capability of T cells to fight cancer in a human clinical setting. This opens up new avenues for cancer treatment, and the novel approach to immunotherapy has already moved into a clinical trial. Read all about it here. | 
